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Cell surface displaya b s t r a c t
In recent years, several cell-based screening technologies for the isolation of antibodies with pre-
scribed properties emerged. They rely on the multi-copy display of antibodies or antibody fragments
on a cell surface in functional form followed by high through put screening and isolation of cell
clones that carry an antibody variant with the desired afﬁnity, speciﬁcity, and stability. Particularly
yeast surface display in combination with high-throughput ﬂuorescence-activated cell sorting has
proven successful in the last ﬁfteen years as a very powerful technology that has some advantages
over classical generation of monoclonals using the hybridoma technology or bacteriophage-based
antibody display and screening. Cell-based screening harbours the beneﬁt of single-cell online
and real-time analysis and characterisation of individual library candidates. Moreover, when using
eukaryotic expression hosts, intrinsic quality control machineries for proper protein folding and
stability exist that allow for co-selection of high-level expression and stability simultaneously to
the binding functionality. Recently, promising technologies emerged that directly rely on antibody
display on higher eukaryotic cell lines using lentiviral transfection or direct screening on B-cells.
The combination of immunisation, B-cell screening and next generation sequencing may open
new avenues for the isolation of therapeutic antibodies with prescribed physicochemical and func-
tional characteristics.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Monoclonal antibodies (mAbs) are among the most successful
and frequently used biotherapeutics. As of March 2012, 34 mAbs
or antibody formats were approved in either Europe or the US, with
a total number of 28 currently marketed molecules [1,2]. About
350 mAb candidates are currently in clinical studies, among them
28 single mAbs and one mAb mixture that are in Phase III corrob-
orating the therapeutic potential of this continuously growing class
of therapeutic agents [3]. For antibody discovery, currently two ap-
proaches are predominant: animal immunisation and surface dis-
play methodologies. Immunisation of wild type or transgenic
animals is an effective method for generating antibodies, but im-
mune tolerance may hinder the generation of neutralizing antibod-
ies when antigens are well conserved or toxic to the respectivespecies [4]. Display technologies such as phage display or microbial
cell surface are based on the in vitro selection from naïve or im-
mune-libraries [5] and overcome limitations of immune tolerance.
Control over selection and screening conditions allow for selecting
speciﬁcities towards deﬁned antigen conformations or epitopes
and in some cases epitopes of the target protein can be addressed
that are not detected by antibodies that have been obtained by
conventional immunisation [6].
Although the vast majority of approved mAbs are chimeric or
humanised antibodies, today more and more entities from phage
displayed antibody libraries and from transgenic rodents with
functional human antibody repertoires enter clinical development
[7,8]. Non-canonical antibodies, e.g. multispeciﬁcs [9,10], other-
wise engineered or artiﬁcial antibodies [11–13] and antibody frag-
ments or domains [14–19] that have been optimized e.g. for
enhanced tissue penetration, pharmacokinetics, or effector func-
tion constitute about half of the anticancer mAbs in the pipeline
[20]. Those antibody derivatives are usually selected from (combi-
natorial) antibody-libraries via high-throughput identiﬁcation
using various display technologies.
The key feature that enables the identiﬁcation and isolation of
favoured candidates from antibody libraries is the linkage between
the antibody variant to the coding genetic information [21]. In gen-
eral, there are ﬁve main display technologies [22] referred to as
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DNA display [23–25], with phage display as the most established
one [21]. The technology of phage display has been extensively
and elegantly described elsewhere [26–29]. This review exclu-
sively focusses on cellular high-efﬁciency screening technologies
of canonical and non-canonical antibody molecules with a special
emphasis on eukaryotic high-efﬁciency screening. Eukaryotic cell
display technologies do not only harbour the beneﬁt of online
and real-time analysis and characterisation of library candidates,
but also have quality control machineries for proper protein fold-
ing which every library member has to pass through before being
displayed on the surface of the cell. [7]. In Escherichia coli, efﬁcient
secretion of functional antibody fragments into the bacterial peri-
plasm and also their display on phage requires co-expression of
chaperones and isomerases indicating that the natural bacterial
secretion machinery has limited capability in generating functional
antibody fragments [30–32]. Using higher or lower eukaryotes for
antibody display, library candidates are believed to be displayed
most likely well folded and can be expected to have better bio-
physical properties compared to binders obtained from phage dis-
play that relies on bacterial protein production. Further potential
advantages include the ability to co-select for high-level expres-
sion and stability of glycosylated IgGs simultaneously to the bind-
ing functionality. In the past, eukaryotic cell display has been
hampered by small library sizes, making direct isolation of
high-afﬁnity binders from naïve libraries improbable. This article
reviews recent improvements and approaches to enlarge or focus
libraries as well as harnessing in vivo afﬁnity maturation strategies
for the fast and effective selection of functional therapeutic
monoclonal antibodies.
2. Antibody formats used for surface display
This section brieﬂy describes commonly used antibody formats
used for surface display without raising a claim of giving a compre-
hensive overview. A more detailed review on antibody formats can
be found elsewhere [33,34]. Fig. 1 shows commonly displayed anti-
body variants. IgG antibodies are dimers of heterodimers compris-
ing two heavy chains and two light chains. They are bivalent and
monospeciﬁc. Each antigen binding site is composed of the variable
domain of the light chain and the variable domain of the heavy
chain. The Fc-part usually mediates effector function e.g. antibody
dependent cell cytotoxicity (ADCC) and complement dependent
cytotoxicity (CDC). Furthermore bispeciﬁcity can be introduced
into the bivalent IgG structure in different ways by desymmetrisa-
tion of the antibody Fc part via engineering residues at the Fc inter-
phase according to a knobs-into-holes principle [35–37].
Bispeciﬁcity can also be achieved using various other formats that
rely on the combination of antibody domains with differentFig. 1. Schematic presentation of commonly used antibody formats for cellular display sy
chain variable fragment (scFv), where the variable domain of the heavy chain (VH) is fused
ﬁlling model of an antibody (taken von PDB 1IGT). CL: constant domain of the light chaspeciﬁcities [34,38]. Display of full length IgG is due to molecule
complexity difﬁcult to achieve in prokaryotic systems and mainly
restricted to eukaryotic cell surface display. Other commonly used
antibody formats consist of antibody fragments and are accessible
by all display methods including phage and ribosomal display.
These include Fab fragments and single-chain variable fragments
(scFv) (Fig. 1B and C). Fab fragments are heterodimers of the VH
and CH1 domain and the VL and CL domain. ScFvs only consist of
the VH and the VL domain connected by a small peptide linker.
More recently, single domain antibodies (dAb) have been gener-
ated based on single human antibody domains of the VH or VL do-
main that have been engineered for high speciﬁcity, afﬁnity and
solubility [39–41]. Fcabs (Fc antigen binding) originate from
immunoglobulin Fc-fragments and represent another recently
engineered class of alternative antibody formats of small size
which in contrast to other alternative scaffolds can elicit immune
effector functions [13]. Camelids and sharks express antibodies
that are composed only of heavy chains. Hence, antigen binding
is mediated by one single domain referred to as VHHs in camelids
and vNARs in sharks. Those antibody fragments are naturally
highly stable and soluble and it has been shown that those mole-
cules can be utilised to generate high-afﬁnity binders
[15,16,19,42,43].
3. Flow cytometry and high-content microscopy
Cell-based screening and selection is essentially conducted by
application of high-throughput ﬂow cytometry or high-content
microscopy [44]. Themost commonmethod used is ﬂow cytometry
(FC) or ﬂuorescence-activated cell sorting (FACS) that allows for
hundreds of thousands of cells per minute to be analysed according
to their size, granularity and ﬂuorescence properties. FC can be ap-
plied for multiplexing, with the simplest example being the com-
bined analysis of antibody binding parallel to cell viability
assessment. But also more elaborate approaches of monitoring up
to 19 different parameters in a single sample by using various
cell-surface markers and intracellular cytokine tags have been
achieved [45], opening theway for distinct and diversiﬁed selection
strategies. Both selection and screening of monoclonal antibodies
presented on the cell surface can be performed by iteratively enrich-
ing cells for both expression level (by display strength) and afﬁnity
(via antigen reactivity). However, time-dependent studies on indi-
vidual cells during screening are not commonly performed and only
possible in low throughput after sorting into single colonies. Hence,
ﬂow cytometry is neither designed for dynamic analysis of single
cells nor observations of spatial localisation of antibodies and target
proteins within a cell after endocytotic uptake.
Microscopy, another frequently used method for single-cell
analysis is well suited for localisation- and time-dependentstems. Left: antibody molecule of the IgG isotype. Middle: Fab fragment and single-
to the variable domain of the light chain (VL) by a small peptide linker. Right: space
in. CH1–CH3: constant domain 1, 2 or 3 of the heavy chain, respectively.
280 A. Doerner et al. / FEBS Letters 588 (2014) 278–287studies, e.g. for assessing internalisation of an antibody, and live-
imaging techniques focus on monitoring individual cell behaviour.
Normally, cells are ﬁxed and hundreds of images are obtained fol-
lowed by image analysis. Limitations of microscopy-based screen-
ing methods are throughput, multiplex readouts, and time spent
on data acquisition. For antibody discovery, initial selection and
screening of large libraries is preferentially carried out applying
ﬂow cytometry and often followed by thorough functional analy-
ses of a smaller set of antibody candidates using microscopy tech-
niques. Table 1 gives a brief overview of advantages and drawbacks
of both technologies.
With recent technology improvements, the beneﬁts of ﬂow
cytometry and cell microscopy have been successfully imple-
mented in new instrumentations aimed at combining the speed
of analysis and the ﬂuorescence sensitivity of ﬂow cytometry with
spatial resolution of digital microscopy in a single device. Laser
scanning cytometry, multispectral imaging cytometry, and spec-
trometric cytometry are promising innovative platforms emerging
as valuable tools in single-cell analysis [46–48].
4. Bacterial surface display
While ﬂow cytometry based microbial display for protein
engineering and the directed evolution of peptides and enzymes
has been applied extensively and successfully [49–51], displaying
full antibodies on bacteria has been challenging in the past. In
recent years, Georgiou and co-workers developed bacterial peri-
plasmic display of so-called E-clonal mAbs [52,53]. For proper
folding conditions, antibody heavy and light chains are secreted
into the periplasm of E. coli, where they assemble into aglycosy-
lated IgGs that are captured by an Fc-binding protein and there-
by become tethered to the outer side of the inner membrane.
After permeabilising the outer membrane, the resulting sphero-
plast clones can be screened by ﬂow cytometry for binding to
ﬂuorescently labelled antigen. Although ﬂow cytometry proved
powerful, the screening of libraries with diversity >108 was tech-
nically challenging. Therefore, in another approach, Mazor et al.
took advantage of full-length IgG phage display as a pre-screen-
ing step to reduce library size and enable subsequent rounds of
FACS screening in E. coli by bacterial periplasmic display. This
procedure could allow for selection from antibody libraries with-
out undersampling and at the same time capitalise on the
advantages of FACS for real-time monitoring and optimisation
of the screening process [54]. Particularly for bacterial surface
display, the restriction to apply FACS screening directly to li-
braries exceeding 108 variants for the enrichment of binders
can be overcome by application of stable high-speed sorting
devices with sorting rates at over 100000 events per second,
where each droplet contains on average at least one cell. How-
ever, long sorting times of several working days may be required
depending on library diversity and intended oversampling.
5. Yeast surface display as a platform technology to select and
evolve antibodies
The yeast Saccharomyces cerevisiae was used for decades as a
useful eukaryotic host for protein production. ParticularlyTable 1
Advantages and drawbacks of ﬂow cytometry and microscopy based discovery technologi
Attributes HT ﬂow cytometry
Cell types Suspension, adherent cell need to be detached
Label-free measurements Forward scatter (size) and side scatter (granula
Throughput Up to 10000 cells/s
Dynamic range High
Spatial measurements Nodisulphide bond-containing proteins as e.g. human antibodies
and fragments thereof can be produced by secretion into the cul-
ture medium making use of the oxidative environment in the
endoplasmatic reticulum and the presence of chaperones that
mediate oxidative folding. Due to the presence of several natural
occurring cell wall-anchored proteins, foreign proteins can be tar-
geted to the outermost cell-surface via fusion proteins containing a
C-terminal glycosylphosphatidylinositol attachment signal (GPI
anchor). In its initial development, pioneered by Wittrup and co-
workers [55], antibody display on the yeast surface relies on the
genetic fusion of antibody coding DNA-sequences in-frame with
the sequence of a favourised cell-wall mannoprotein. During for-
mation of the cell wall, e.g. in budding daughter cells, the fusion
protein is targeted to the cell surface through its C-terminal GPI-
attachment signal. To date, several cell wall proteins have been
identiﬁed that are all proven to be capable of displaying different
fusion proteins on the cell surface. These include for instance a-
agglutinin [55], Flo1p [56,57], and a-agglutinin [58]. Among these,
the a-agglutinin-system has shown to be the most successful one.
Thus far, it has been applied to display and evolve various proteins
like enzymes, human growth factors, cytokines, cell surface receptors,
the human MHC complex and isolate antibody fragments like scFv,
Fab and scFab fragments and so called Fcabs and evenwhole antibod-
ies with prescribed binding characteristics out of libraries [55,59–61].
A-agglutinin is one of the two mating type speciﬁc agglutinins
that mediate cell–cell contact during mating of appropriate yeast
cells [62]. It is formed by one core-subunit Aga1p, which is linked
to a smaller binding-subunit Aga2p through two disulphide
bridges. Due to the GPI-attachment-signal of Aga1p the core-sub-
unit covalently anchors the whole complex to the cell wall
(Fig. 2). The modular structure of a-agglutinin furthermore enables
the fusion of the heterologous protein to be displayed to the C- or
N-terminus of Aga2p [63] whereas single-unit GPI-proteins only
allow an N-terminal fusion of heterologous proteins because of
the required C-terminal GPI-attachment signal. One exception is
Flo1p which can attach and immobilize foreign proteins non-cova-
lently via fusion to its N-terminal ﬂocculation functional domain
that is supposed to bind to carbohydrate units on the cell-surface
[64,65]. The importance of orientation of yeast displayed proteins
has recently been shown for an anti-CD3e scFv since it showed a
3-fold higher afﬁnity when being displayed with a free N-terminus
and not linked to the subunit Aga2p [63].
The overexpression of chromosomal encoded AGA1 and the epi-
somal encoded AGA2-fusion is driven by the inducible Gal1-pro-
moter. Both subunits are equally expressed and associate in the
endoplasmatic reticulum. Following galactose-induced expression,
each yeast cell displays approximately 104–105 copies of the fu-
sion-protein on its surface [55]. Detection of surface-exposed fu-
sion proteins occurs by virtue of epitope tags or by means of its
activity, which is in case of an antibody its binding-afﬁnity to a sol-
uble antigen. The detection is typically carried out with the respec-
tive biotinylated antigen and a secondary reagent such as
streptavidin-conjugated ﬂuorophores, or an otherwise labelled
antigen.
The most powerful advantage of yeast display compared to
other high-throughput screening methods like phage display is
its compatibility with ﬂuorescence-activated cell sorting (FACS)es (adapted from [28]).
High content microscopy
Adherent, suspension cells need to be immobilised
rity) are standard Brightﬁeld imaging with some instruments
Up to 100 cells/s
Low
Yes
Fig. 2. Simpliﬁed illustration of yeast surface display with Aga2p-fusion proteins
where the protein of interest (POI) is fused to the C-terminus of Aga2p (left) and
with alternative anchor proteins (APP) where it is fused to the N-terminus of the
anchor protein (right). Below, the respective genetic arrangements are shown,
where SP stands for a signal peptide, which enables the secretion of the fusion
protein to the endoplasmatic reticulum and GOI for gene of interest. In addition, the
detection with a certain ﬂuorescent-labelled antigen, the fusion protein can be
detected for ﬂow cytometric purposes with tag-speciﬁc antibody conjugates (red
and green).
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and thus the convenient screening of large libraries. This provides
the possibility to highly enrich binding clones and to discriminate
between different afﬁnities of distinct clones. This is in contrast to
other in vitro display technologies like phage display even in terms
of low afﬁnity interactions that can be detected with yeast display
due to its high sensitivity that is caused by high surface densities of
the binding protein [55]. FACS offers the additional possibility to
normalize for protein display level during sorting and to screen
for protein stability [66,67]. Yeast display further enables the direct
characterisation of afﬁnity and binding epitopes by antigen titra-
tion and ﬂow cytometric analysis without the need of reformatting
expression plasmids after selection [68]. This is of interest, if a
large number of clones have to be characterised after selection.
For initial screening of large libraries magnetic cell pre-sorting
can be performed prior to FACS [69].
A direct comparison of yeast and phage display performance for
the de novo isolation of scFvs from an anti-HIV-1 immune library
was done in 2007 by Burton and colleagues. They subcloned an
existing scFv phage library into a modiﬁed yeast-display vector
and performed FACS for HIV-1 protein gp120 binders. To enable
a direct comparison of both technologies they conﬁrmed a uniform
quality and sequence composition of the libraries in advance. After
selection and clone analysis it turned out, that the selection proce-
dure using the yeast displayed library revealed the same clones
that were isolated from the phage-library and an additional set
of new clones that were not discovered from the phage library.
These new clones all showed low nanomolar KD values that one
would expect from an immune library. From this result they con-
cluded that with yeast display the library was sampled more com-
prehensive than with phage and that this is in particular important
for the isolation of rare antibodies from large libraries [70].
5.1. Applications of yeast surface display
Yeast surface display is perfectly suited for protein engineering
and library screening especially for de novo selection approachesand afﬁnity maturation. Several studies showed the capability of
protein engineering in combination with directed evolution and
yeast surface display to ﬁne tune scFv binding properties. In this
case, through introducing mutations into an existing ﬂuorescein-
speciﬁc scFv-fragment, a mutant variant was isolated from a li-
brary of 105 clones with a 2.2-fold improvement in dissociation
rate constant [55]. In 2000 the same parental scFv 4-4-20 was used
to engineer the highest afﬁnity for a monovalent binding protein/
ligand interaction until then with an equilibrium dissociation con-
stant of KD = 48 fM [71]. Recently, Tillotson et al. successfully ap-
plied yeast surface display for engineering the binding afﬁnity of
a transferrin receptor-speciﬁc scFv in a kinetic screen by using
detergent-solubilised cell lysate as an antigen source. It was shown
that even in the presence of strong detergents yeast displayed
scFvs retained their binding speciﬁcity and that the binding afﬁnity
could be improved by up to 7-fold [72]. In addition, not only anti-
body-based proteins were successfully engineered in the past, but
alternative binding scaffolds as well. Cochran and co-workers mu-
tated loop regions of an AgRP cystine-knot peptide for engineering
speciﬁcity to avb3 integrins with low nanomolar afﬁnity by yeast
surface display [73]. Likewise, yeast display was used to engineer
higher afﬁnity T-cell receptors [74], scaffold proteins based on
10th human ﬁbronectin type III domain [75], or the hyperthermo-
philic Sso7d scaffold [76].
In addition to single-chain Fv antibody domain fusions, it has
also been shown that heterodimeric Fab fragments can be effec-
tively displayed on the yeast surface and screened for afﬁnity
improvement. To this end, Fab-HC was fused to the C-terminus
of Aga2p and Fab-LC was secreted solubly from an additional plas-
mid under control of the identical Gal1-promoter [77]. Further-
more, it has been shown that yeast is capable of displaying
single-domain antibodies, like VHH-fragments of llama heavy-
chain antibodies, known as nanobodies [75]. For example, a S. cere-
visiae-displayed non-immune llama VHH-library for botulinum
neurotoxin binding variants was used to isolate neurotoxin-bind-
ing VHH-variants that also proved to show inhibition of toxin
activity [78].
In recent years, several examples of antibody display in the
yeast Pichia pastoris have been described that also rely on genetic
fusion of the antibody moiety to a cell wall protein [79–81]. For
example, Ryckaert et al. showed the display of nanobodies of an
immunised llama library on P. pastoris using the S. cerevisiae anchor
a-agglutinin for displaying the library on the cell surface of glyco-
engineered P. pastoris [81].
Interestingly, the C-terminal constant domain of an antibody Fc
part can also be engineered for antigen binding. Through the engi-
neering of loop-regions in the CH3 domain of IgG-Fc, Fc-fragments
with new binding properties were generated by yeast surface dis-
play. At the C-terminus of the CH3 part a binding site for the Her2/
neu receptor was identiﬁed by FACS-screening of combinatorial li-
braries displayed on yeast. One isolated clone showed a 69 nM
binding afﬁnity after afﬁnity maturation for Her2/neu and still
showed functional binding sites for protein A, FcRn and CD69
which demonstrates the structural integrity of the whole Fc part.
Furthermore the engineered Fc part (called Fcab, Fc antigen bind-
ing) mediates antibody-dependent cellular cytotoxicity which
means, that it contains all IgG-features such as antigen binding
and effector function in a much smaller protein [13].
5.2. Novel yeast surface display formats
In conventional yeast display settings with GPI-anchor proteins,
the foreign protein is expressed as part of the cell wall. Alternative
display strategies rely on the synthesis of the antibody with an
adaptor protein or peptide that allows for capturing on the cell sur-
face. The major advantage of antibody capturing approaches lies in
282 A. Doerner et al. / FEBS Letters 588 (2014) 278–287the fact that it is possible to switch between antibody surface dis-
play for screening and antibody secretion and accumulation in the
culture medium for functional characterisation of individual candi-
date antibodies. We have recently applied the antibody Fc-binding
ZZ-domain derived from S. aureus protein A as a capturing agent for
secreted antibody Fc (L. Rhiel, unpublished results). It makes use of
the fact that the ZZ-domain can be functionally displayed on S.
cerevisiae and retains its ability to bind soluble IgG-molecules
[82–84]. IgG-molecules are solubly secreted from respective hea-
vy-chain and light-chain plasmids or bicistronic vectors, carried
by the same cell and become captured on the cell surface by the
ZZ-domain upon secretion (Fig. 3A). In contrast to the conventional
Aga2-display, no additional subcloning steps are necessary for sub-
sequent soluble protein production and biochemical characterisa-
tion, if the expression of ZZ-domain and antibody-chains are
under control of distinct promoters and can therefore be regulated
separately. This clearly simpliﬁes the screening for biological func-
tion in the following downstream process.
In a very elegant approach, switchable secretion and display in
glyco-engineered P. pastoris was achieved by taking advantage of
homo-dimerisation of the Fc portion of an IgG molecule to aFig. 3. Novel cell surface display formats. (A) Scheme of non-covalent yeast surface displ
and captured by the ZZ-domain. (B) Representation of the Fc-Sed1p antibody display syste
Sed1p. Co-expression of a secretable full length IgG molecule leads to heterodimers with
soluble full length IgG occurs with an equal probability which leads to the secretion of a b
expressed as a fusion to a biotin acceptor peptide. The co-expressed biotin ligase attaches
avidin, which is attached to the yeast cell wall. (D) scFv antibody display on mammali
transmembrane domain of human platelet-derived growth factor receptor (PDGFR). Thesurface-anchored ‘‘bait’’ Fc (Fig. 3B). This method was successfully
applied to the isolation of high-afﬁnity anti-PCSK9 antibodies from
a library that was created by mating P. pastoris haplonts containing
either light chain or heavy chain IgG libraries [85].
Initial efforts of yeast surface display of full-length IgG were
hampered by the ﬁnding that full-length IgG secretion is very inef-
ﬁcient in S. cerevisiae [86]. Recently, enhanced secretion of IgG
molecules from S. cerevisiae was achieved with a new secretory
sequence [87]. This secretory sequence was discovered by screen-
ing a mutagenic library of the mating factor alpha signal peptide
for enhanced IgG-secretion. Functional display and immobilisation
of full-length IgG-molecules on yeast cells was achieved with the
SECANT display technology [88]. To enable surface attachment
of secreted IgG to the antibody-producing cell, a recognition se-
quence for the biotin ligase BirA was fused to the antibody heavy
chain. Upon co-expression of BirA the heavy chain was biotinylated
and after soluble secretion re-captured to the cell surface to which
biotin-binding avidin was coupled. The IgG-display was completed
by co-expression and soluble secretion of the corresponding anti-
body light chain (Fig. 3C). A similar strategy that relies on antigen
immobilisation on the cell surface was used to capture secreteday with a Fc-binding ZZ-domain as a C-terminal fusion to Aga2p. The IgG is secreted
m. The hinge region and the Fc-fragment are fused to the cell wall-anchored protein
the Fc-Sed1p fusion resulting in a displayed monovalent IgG molecule. Assembly of
ivalent IgG molecule. (C) SECANT yeast display platform. The antibody molecule is
biotin to the acceptor peptide. The biotinylated antibody is secreted and captured by
an HEK-293T cells. The scFv is fused to a myc-tag for display detection and to the
respective gene arrangements are shown below.
A. Doerner et al. / FEBS Letters 588 (2014) 278–287 283ﬂuorescein-binding IgG-molecules via binding to the ﬂuorescein-
functionalised S. cerevisiae cells [89].
5.3. Yeast mating technology
Antibody yeast display offers great opportunities for afﬁnity
maturation. This is in contrast to phage display, where it can be
more elaborate to distinguish kinetic binding properties by nor-
malisation of display ratios during panning. A critical point in anti-
body yeast selection strategies is the generation of large molecule
libraries, because this is regarded to be a prerequisite for obtaining
high-afﬁnity antibodies from libraries [5]. For years, transforma-
tion efﬁciencies of yeast cells compared to E. coli were several or-
ders of magnitude lower. In recent years systematic optimisation
of transformation parameters resulted in robust protocols that al-
low one to routinely obtain 108 to 109 transformants in a single
working day [90]. Moreover, yeast mating provides an additional
option to greatly enhance diversity in yeast-based selection ap-
proaches, especially when dealing with heterodimeric molecules
like Fab fragments and IgG-molecules. Mating of compatible hap-
loid yeast strains was used as a strategy to combine VH and VL
genes in a large library. In combination with error-prone polymer-
ase chain reaction chain shufﬂed libraries with diversities up to
5  109 are accessible and particularly useful for antibody afﬁnity
maturation [85,91,92]. Selected diploid cells can be reformatted
into haploid daughter cells by induction of natural sporulation
and the resulting haplonts can be used for further mating and
selection approaches.
6. Mammalian display
Microbial display technologies allow for the isolation of
antibodies with prescribed speciﬁcities and afﬁnities. However,
important features for large-scale antibody production using
higher eukaryotes as high-level expression, reduced aggrega-
tion and correct glycosylation can hardly be implemented in
the screen. Hence, selection methodologies for mammalian
cell-displayed antibodies would solve those shortcomings and
supply a potentially superior approach. Albeit establishing ro-
bust expression and genotype–phenotype linkage has been
challenging, several interesting technologies have emerged
recently.
Ho and Pastan showed that single-chain antibodies (scFvs)
can be displayed on the surface of human embryonic kidney
293T (HEK293T) cells and used for afﬁnity maturation (Fig. 3D)
[93]. Adding a degree of complexity, also full-length functional
antibodies were described to be presented on the surface of
mammalian CHO cells applying the Flp-In™ technology (Invitro-
gen) [94]. Here, library diversity was generated by recombinase-
mediated chromosomal DNA integration so that each host cell
contained one diversiﬁed copy of the gene of interest in the gen-
ome. High and clone-to-clone comparable expression was en-
sured by utilising a hot-spot integration site. FACS yielded
antibodies with signiﬁcantly improved neutralizing activity and
afﬁnities could be enhanced in one single round by more than
500-fold. For enhanced antibody display efﬁcacy, also the natural
expression apparatus of B-cells can be exploited: for retroviral B
lymphocyte display (‘‘Retrocyte Display’’) [95], antibody heavy
and light chains are encoded by separate retroviral expression
vectors within B-lineage cells to yield stably expressed fully hu-
man monoclonal antibodies on the surface of the B-lineage cells
in the form of B-cell receptors. Antibody libraries can be
screened by FACS in 3–5 rounds of selection for the respective
functionality with recovery of potential candidates and subse-
quent genomic PCR cloning and sequencing for future expression
in other mammalian expression systems. When using naturallyantibody producing B-lineage cells, all necessary co-factors
(chaperones, glycosylation enzymes, etc.) that ensure proper pro-
tein folding, antibody heavy-light chain assembly, glycosylation
and disulphide bridge formation are present throughout discov-
ery that could be absent in non-lymphocyte, lower eukaryotic
or prokaryotic expression systems.
In contrast to previously described methods, Beerli and col-
leagues directly isolated B-cells speciﬁc for an antigen of interest
from peripheral blood mononuclear cells (PBMC) of human donors
[96]. Recombinant, antigen-speciﬁc single-chain Fv (scFv) libraries
were generated from this pool of cells and screened by mammalian
cell surface display by using a Sindbis virus expression system. This
method allowed isolating antigen-speciﬁc antibodies fragments by
a single round of FACS which had to be re-formatted to full anti-
bodies and expressed in different, standard mammalian expression
systems. This additional step was circumvented in a recent work
by Li and co-workers who isolated a human anti-EGFL7 antibody
via full length mammalian cell display by a combination of mag-
netic beads and cell ELISA screening [97]. Both elegant and straight
forward approaches nevertheless suffer from the prerequisite of an
immunised healthy volunteer or patients having already developed
speciﬁc antibodies against the target of interest.
In vaccinia virus display as another mammalian display system
exploiting viruses, mammalian cells are co-infected with an anti-
body heavy chain library and an additional light chain library or
cocktail of vaccinia recombinant human light chains [98]. Anti-
body-displaying virus particles released from infected cells can
be concentrated by centrifugation and selected for target-speciﬁc
binding on antigen-coated magnetic beads. The selected viruses
are expanded and further enriched by an additional round of selec-
tion. The antibodies are also expressed on the mammalian cell sur-
face, so that, in a ﬁnal step, infected cells can be stained with
antigen and single positive binders can be separated for the subse-
quent recovery of heavy and light chain pairs to be cloned in an-
other expression vector for further characterisation.
As the generation of antibody diversity for mammalian cell dis-
play is a crucial and challenging step and prerequisite for any
selection process, several new approaches were developed in re-
cent years. For example, Bowers and co-workers enhanced low-
afﬁnity antibodies derived from an IgM via isolation of antigen-
binding naïve B-cells and reformatting IgM variable domain diver-
sity to produce a library of germline full-length IgG antibodies in
HEK293 cells. Making use of afﬁnity maturation processes that nat-
urally occur in B-cells, i.e. somatic hypermutation and class switch-
ing, generated high-afﬁnity antibodies that could be selected by
mammalian cell display [99]. The maturation of one of the antibod-
ies to low picomolar afﬁnities indicates the overcoming of many
previous limitations of mammalian cell display, enabling direct
selection and maturation of antibodies as full-length, glycosylated
IgGs. Likewise, mining the natural antibody repertoire by immun-
ising animals in combination with generating additional diversity
by introduction of random mutations allowed for the rapid gener-
ation of high-afﬁnity humanised antibodies [100]. To this end,
rearranged IgH D(J) regions were ampliﬁed from the spleen and
lymph tissue of immunised mice, fused with a limited repertoire
of human germline heavy chain V-genes to form intact humanised
heavy chains, and paired with a human light chain library. Com-
pleted heavy and light chains were assembled for mammalian cell
surface display and transfected into HEK 293 cells co-expressing
somatic hypermutation inducing activation-induced cytidine
deaminase (AID). Numerous clones were isolated by ﬂuores-
cence-activated cell sorting, and afﬁnity maturation resulted in
the rapid evolution of high-afﬁnity antibodies. In a further study,
somatic hypermutation along with other methodologies was ap-
plied for extreme thermostabilisation and afﬁnity maturation. A
highly stable, high-afﬁnity, full-length antibody with a Tm over
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hour and a 95-fold improved antigen-binding afﬁnity could be se-
lected [101].
In a similar approach applying gene conversion on chicken B-
cells, which is the main immunoglobulin variable region diversiﬁ-
cation process in chicken, yielded expanding libraries of antibodies
displayed at the cell surface as membrane-bound IgM [102]. This
technology, named ADLib system (Autonomously Diversifying Li-
brary system) is compatible with selection on magnetic beads con-
jugated to target antigen of interest and could be used for rapid
identiﬁcation of IgM molecules as well as for afﬁnity maturation
based on the genetic enhancement of hypermutation.
The isolation of antibodies with an effector function is usually a
complex two-step process in which molecules are ﬁrst screened for
binding and then for function. Lerner and co-workers recently pub-
lished a new lentiviral screening method that allows for the direct
selection for function [103]. A combinatorial antibody library was
constructed in lentiviruses. A paramount attribute to this system
is the ability to select heterodimeric bispeciﬁc antibodies because
more than one virus can potentially infect a single cell. Applying
this method, potent antibody agonists of erythropoietin could be
selected. These bispeciﬁc antibodies (heterodimers recognising
the same molecule at two different epitopes) were obtained. In a
more recent very elegant approach the same group established a
high-throughput system for the functional screening of receptor
agonists by coupling a ﬂuorescence readout to the receptor of
interest and validated their system for the selection of agonist anti-
bodies for the thrombopoietin receptor [104].
7. B-cell immunisation and deep sequencing
All display approaches described above rely on initial cloning of
heavy and light chain diversity and in most cases, information
about endogenous pairing of heavy and light chains is lost. To over-
come this problem, single B-cells from immunised mice were
deposited in high-density microwell plates and lysed in situ. mRNA
was captured on magnetic beads, reverse transcribed, ampliﬁed by
emulsion PCR and analysed by deep sequencing. Pairing the most
abundant VH and VL genes based on their relative frequencies fol-
lowed by automated gene synthesis and expression as recombi-
nant antibodies in bacteria or mammalian cells led to 78%
antigen speciﬁc antibodies (21/27) with nanomolar binding afﬁni-
ties, indicating the possibility to mine high-afﬁnity antibody se-
quences by antibody cDNA sequencing of single B-cells [105].
Moreover, B-cells that produce an antigen-binding antibody can
be pre-screened prior to sequence analysis [106]. To this end, stim-
ulated B-cells from peripheral blood mononuclear cells (PBMC) of
rheumatoid arthritis (RA) patients were proﬁled at the single-cell
level in a large array of sub-nanoliter nanowells, assessing both
the phenotype of the cells and their ability to secrete cyclic-citrul-
linated peptide (CCP)-speciﬁc antibodies. Antibody-secreting sin-
gle B-cells were retrieved by automated micromanipulation, and
ampliﬁcation of the VH and VL was performed prior to recombi-
nant expression. The methodology offers a simple, rapid, and
low-cost platform for isolation of antibodies from low numbers
of input cells and could be easily adapted for isolation and charac-
terisation of auto-reactive antibodies in other autoimmune dis-
eases or neutralising antibodies after immunisation. Similarly,
antibodies against hepatitis B virus and inﬂuenza viruses were iso-
lated from single antibody-secreting cells by application of micro-
well array chips with a capacity of up to 234000 individual cells
[107]. The method was termed ‘‘immunospot array assay on a
chip’’ (ISAAC) for which antibody-displaying cells were individu-
ally cultured on a chip. Amounts of secreted antibody were ana-
lysed applying a ﬂuorescently labelled anti-human IgG detectionantibody and afﬁnity was assessed by staining with biotinylated
antigen and Cy3-streptavidin. A high ratio of bound antigen to
antibody secretion indicated high-afﬁnity antibodies. Best single
antibody-secreting cells could be selected from a large population
of primary lymphocytes and the respective human antibody with
virus-neutralising activities expressed within a week.
A slightly different, proteomics approach was taken by Cheung
and co-workers that identiﬁed antigen-speciﬁc antibody se-
quences directly from circulating polyclonal antibodies in the ser-
um of an immunised animal [108]. The approach involved afﬁnity
puriﬁcation of speciﬁc antibodies followed by nano-ﬂow liquid
chromatography coupled to tandem mass spectrometry. In paral-
lel, the B-cell antibody repertoire was mined by deep sequencing.
Now, high-conﬁdence peptide MS spectral matches of antibody
variable regions could be retrieved by searching the reference se-
quence database. Finally, VH and VL sequences were paired and ex-
pressed as recombinant monoclonal antibodies. Using this
technology, monoclonal antibodies for ﬁve antigens from the sera
of immunised rabbits and mice could be isolated. This technology
may aid the discovery and development of vaccines and antibody
therapeutics, and help us gain a deeper understanding of the hu-
moral response.
8. Conclusions and outlook
The classical hybridoma technology that was introduced in the
1970s of the last century by Köhler and Milstein still is a state of
the art methodology for the isolation of monoclonal antibodies
[109]. With the introduction of the human antibody repertoire into
mice, it is now possible to raise antibodies or antibody fragments
of human genetic origin in animals using hybridoma technology
[110]. With the invention of phage display in the mid 1980s
[111], the isolation of antibodies and antibody fragments with de-
ﬁned binding characteristics was possible using E. coli as phage
particle- and antibody fragment-producing host. Based on the pio-
neering work of Wittrup and co-workers in the mid 1990s [55],
yeast surface display emerged as an alternative technology which
allows for in situ single cell analysis of antigen binding and also
automatically implements aspects of correct folding and sufﬁcient
stability of the displayed protein molecule due to the presence of
an inherent quality control mechanism in eukaryotes, the unfolded
protein response [112]. Now, 108 to 109 library members can be
generated by yeast transformation. This number approaches trans-
formation efﬁciencies that are typical for phage display library
generation. Moreover, the natural recombination process of yeast
cell mating allows for light and heavy chain shufﬂing simply by
mating two haploid yeast strains, where one carries the genetic
information for the heavy chain and the other for the light chain.
Through combination of initial library screening by FACS followed
by afﬁnity maturation by in vitro codon variation and/or mating-
mediated chain shufﬂing, antibodies can be generated with very
impressive afﬁnity and speciﬁcity proﬁles.
In recent years, single-cell high-throughput screening of anti-
body repertoires that were generated in higher eukaryotes showed
to be rather successful. A very promising approach is the expres-
sion, surface display and screening of antibodies in mammalian
cells that have been engineered to provide the antibody afﬁnity
maturation machinery of B-cells. As a consequence, consecutive
rounds of screening and somatic hypermutation allow for the con-
tinuous screening of high-afﬁnity binders [99–101]. With the rapid
development of high-throughput sequencing technologies, it is
nowadays possible to determine the antibody amino acid sequence
directly from single B-cells taken from immunised donors which
even can obviate the need to enrich cells that bind the antigen of
interest [105,113].
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further in substituting cells for antibody production and display by
water in oil droplets that contain all components required for pro-
tein synthesis. In vitro compartmentalisation (IVC) is a method to
achieve coupling of phenotype to genotype by generation of small,
aqueous compartments by mixing water, surfactants, and oil. The
water compartments are surrounded by an oil phase and can
harbour single genes that are competent for transcription and
translation. These cell-like droplets can therefore be used in ﬂow
cytometry-based selections of large libraries with a high degree
of control over selection conditions and stringencies [24]. IVC has
been used successfully for generation of a scFv library of
109–1010 genes by mixing the gene variants with E. coli transcrip-
tion-translation extract and mineral oil to yield about 1010 droplets
in which about 90% contained one segregated antibody gene only.
Expression of domain antibodies in a fusion with a DNA-binding
domain present on the applied plasmid created genotype-pheno-
type linkage and enabled selection for improved afﬁnity in equilib-
rium and off-rate conditions [114]. Sumida and colleagues
described IVC in combination with DNA display that allows the
linking of an oligomeric protein and its encoding DNA or mRNA
with multiple ORFs and thus is applicable to heterodimeric Fab
fragments [115,116]. They identiﬁed conditions under which it
was possible to enrich Fab fragments 106-fold over three rounds
of afﬁnity selection. Furthermore, more stable Fab fragments could
be selected by applying heat treatment as a selection pressure.
Since this method has all advantages of both phage display and to-
tally in vitro display, it represents a new option for antibody selec-
tion or optimisation.
To conclude, with the implementation of numerous methods
for antibody library screening using different screening formats,
a bundle of screening technologies are nowadays available to
isolate high-afﬁnity antibody binders to nearly any given target
in short time. It remains a challenge to implement other impor-
tant and desired features beyond antibody binding into the
screening process as high folding and oxidation stability, low
tendency to aggregate, deﬁned glycosylation pattern, absence
of T-cell epitopes, and efﬁcient recruitment of other components
of the immune system. There is no doubt that innovative novel
approaches can be expected to show up in next years that will
implement as many as possible of these aforementioned quality
parameters into early antibody library screening. This may hope-
fully enhance the likelihood that antibody molecules obtained by
multi-parameter library mining prove full functionality in clinical
trials.
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